These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 9371508

  • 1. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM, Reese JS, Koç ON, Lee K, Schupp JE, Gerson SL.
    Cancer Res; 1997 Nov 15; 57(22):5093-9. PubMed ID: 9371508
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
    Lee K, Gerson SL, Maitra B, Koç ON.
    J Hematother Stem Cell Res; 2001 Oct 15; 10(5):691-701. PubMed ID: 11672516
    [Abstract] [Full Text] [Related]

  • 5. Human long-term culture initiating cells are sensitive to benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and protected after mutant (G156A) methylguanine methyltransferase gene transfer.
    Koç ON, Reese JS, Szekely EM, Gerson SL.
    Cancer Gene Ther; 1999 Oct 15; 6(4):340-8. PubMed ID: 10419052
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL.
    Hum Gene Ther; 1999 Nov 20; 10(17):2769-78. PubMed ID: 10584923
    [Abstract] [Full Text] [Related]

  • 8. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.
    Davis BM, Reese JS, Lingas K, Gerson SL.
    J Hematother Stem Cell Res; 2003 Aug 20; 12(4):375-87. PubMed ID: 12965075
    [Abstract] [Full Text] [Related]

  • 9. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP, Willson JK, Markowitz SD, Zborowska E, Zaidi NH, Liu L, Gordon NH, Gerson SL.
    Cancer Res; 1997 Nov 01; 57(21):4817-23. PubMed ID: 9354444
    [Abstract] [Full Text] [Related]

  • 10. Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
    Maze R, Kurpad C, Pegg AE, Erickson LC, Williams DA.
    J Pharmacol Exp Ther; 1999 Sep 01; 290(3):1467-74. PubMed ID: 10454526
    [Abstract] [Full Text] [Related]

  • 11. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
    Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL.
    J Clin Invest; 2003 Nov 01; 112(10):1561-70. PubMed ID: 14617757
    [Abstract] [Full Text] [Related]

  • 12. Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice.
    Allay JA, Davis BM, Gerson SL.
    Exp Hematol; 1997 Sep 01; 25(10):1069-76. PubMed ID: 9293904
    [Abstract] [Full Text] [Related]

  • 13. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA, Xu-Welliver M, Crone TM, Kanugula S, Pegg AE.
    Biochem Pharmacol; 1999 Jul 15; 58(2):237-44. PubMed ID: 10423163
    [Abstract] [Full Text] [Related]

  • 14. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
    Loktionova NA, Pegg AE.
    Cancer Res; 1996 Apr 01; 56(7):1578-83. PubMed ID: 8603405
    [Abstract] [Full Text] [Related]

  • 15. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL, Pollok KE, Bailey BJ, Liu N, Hartwell JR, Williams DA, Erickson LC.
    Mol Cancer Ther; 2003 Dec 01; 2(12):1321-9. PubMed ID: 14707273
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
    Marathi UK, Dolan ME, Erickson LC.
    Cancer Res; 1994 Aug 15; 54(16):4371-5. PubMed ID: 8044784
    [Abstract] [Full Text] [Related]

  • 20. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells.
    Allay JA, Dumenco LL, Koc ON, Liu L, Gerson SL.
    Blood; 1995 Jun 01; 85(11):3342-51. PubMed ID: 7756667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.